Ikaria(R) Named Private Company of the Year by New Jersey Technolo... (ent of hepatorenal syndrome Type 1. Ikar...)

Ikaria(R) Named Private Company of the Year by New Jersey Technology Council

Date:11/21/2008

ent of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

1. INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, thus may cause airway inflammation and damage. Methemoglobin, NO2, and Fi2 should be monitored during nitric oxide administration.

For more information on INOmax, including important safety information and full prescribing information, please visit www.inomax.com.

    CONTACTS

    Samina Bari                                  Jason Rando/Jen Saunders
    Ikaria                                       The Ruth Group
    (908) 238-6372                               (646) 536-7025/7011
    samina.bari@ikaria.com                       jrando@theruthgroup.com
                                                 jsaunders@theruthgroup.com

SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. American Board of Internal Medicine President Named to Alzheimers Study Group
3. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
4. Pharmaxis Establishes Named Patient Program for Bronchitol
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
7. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
8. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
9. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million

Post Your Comments:

(Date:12/4/2009)..., ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -...se company developing medical countermeasures agai...ay the presentation of new data from the Company,s...zed recombinant Protective Antigen (rPA) based ant...er 16 months at various temperatures up to and inc...

(Date:12/4/2009)..., SAN DIEGO, Calif., Dec. 4 Sunev...ce company, today announced the appointment of Phi...fficer. In this role, Mr. Ranker will lead all Su...s including finance, accounting, IT, IR, administr...the Company,s senior management team. ,, "One ...

(Date:12/4/2009)..., BETHESDA, Md., Dec. 4 Drs. Neal ...prostate-specific antigen (PSA) recurrence from th...iochemical recurrence rate in a Phase III pivotal ...ection) or monthly leuprolide in prostate cancer p...ate cancer patients who received FIRMAGON 240/80 m...

Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4 PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3 Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4 Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2 Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3 Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4 Middle Age Heart Risk Factors Shorten Mens Lives 57598 1 Middle Age Heart Risk Factors Shorten Mens Lives 57598 2 Middle Age Heart Risk Factors Shorten Mens Lives 57598 3 Northwest Hospital 26 Medical Center to Join UW Medicine 57596 1 Northwest Hospital 26 Medical Center to Join UW Medicine 57596 2 Northwest Hospital 26 Medical Center to Join UW Medicine 57596 3 U S Chamber 3A Medical Liability Reform Must Have Teeth to be Effective 57594 1

[0] PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop [0] Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer [0] Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial

...r and Imaging Study) Results Demonstrate ...SAN DIEGO, Calif., Sept. 2 Volcano,Corporation (N...nufacturer of,intravascular ultrasound (IVUS) and ...oday the use of its VH(R) IVUS (Virtual Histology ...d Biomarker and Imaging Study). In,the study, Volc...

...sty and Stenting Safe and Effective in Patients ...t Surgery, WASHINGTON, Sept. 1 Data announced to...atients with very complex coronary,artery disease ...nd,drug-eluting stents rather than open-heart surg...hy and Interventions (SCAI). The one-year results,...

Other Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2 Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3 Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4 SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2 SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3

Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease

(Date:12/4/2009)...rsity researchers, from the School of Medicine,s D...ic pathways by which products of lipid peroxidatio..., are metabolized. The pathways were identified by... analysis. The findings shed new light on the mech...butyrate, also known as "the date rape drug." The ...

(Date:12/4/2009)...ure done immediately or 3 weeks later, study shows...Timing of surgical repair or reconstruction of mul...t outcome, a new study has found. , Multiple-li...slocations that can occur in high-impact car crash...rm surgery to repair these injuries hasn,t been de...

(Date:12/4/2009)...r Applauds Historic Effort but Points out Potentia...n Final Health Care Reform ,, NEW YORK, Dec. ...rnal of Medicine today published a Perspective o...hored by Irwin Redlener, M.D., president, Children...isaster Preparedness and Professor of Clinical Pop...

(Date:12/4/2009)...through hookah, research shows , , FRIDA...afer than cigarettes for smoking tobacco, research...oke tobacco with a water pipe inhale carbon monoxi... disease and nicotine addiction. , The study in...bacco using a water pipe and a single cigarette. A...

(Date:12/4/2009)... Dec. 4 When the spread ...epartment of Health Services needed to get more in...fore. Join Sonic Foundry, Inc. (Nasdaq: SOFO ),...sting and knowledge management, for a live webinar... of Health Services, will share how in-house webca...

Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2 Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2 Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2 Health News:Water Pipes No Safer Than Cigarettes 2 Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2 Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3

[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'[0] Timing of Multiple-Ligament Knee Surgery May Not Matter [0] New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform [0] Water Pipes No Safer Than Cigarettes [0] Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications

...s Corp. (Nasdaq:,HMSY) today announced that it wil...onference, which will be held January 7-10, 2008 a...: http://www.newscom.com/cgi-bin/prnh/20030304/NY...ast of the Company,s presentation can be accessed ...

...nix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announc...porate overview, including an update of the compan..., at the upcoming JP Morgan 26th,Annual Healthcare...entation can be accessed,under "Calendar of Events...

...am for Lead Product, MENLO PARK, Calif., Dec. 20 ...t it has completed a private placement financing,r...opment of the company,s,novel antiplatelet therapy...on,from Prospect Venture Partners, Ridgeback Capit...

...-Opportunities program of Agriculture and ..., ON, Dec. 20 /PRNewswire-FirstCall/ - Bioniche Li...hnology-driven Canadian,biopharmaceutical company,... Ontario. The $5 million repayable,contribution ha...

..., 2007 Wiley-Blackwell, the scientific, technical...n Wiley & Sons, Inc (NYSE: JWa), (NYSE: JWb), and ...anisation dedicated to improving healthcare decisi...World Banks list of low-income economies (countrie...

...dds, study found , THURSDAY, Dec. 20 (HealthDay Ne...cy can boost a child,s risk of developing allergie...nska Institute, Stockholm, analyzed questionnaires...s, 2 years and 4 years. In addition, the researche...

Other Medicine News:Health News:Cogentus Pharmaceuticals Completes $62.5 Million Private Financing 2 Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 2 Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 3 Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 4 Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 5 Health News:Low-income countries now have free, one-click access to Cochrane Library 2 Health News:Parents' Smoking Boosts Child's Allergy Risk 2

HMS Holdings Corp. to Present at 26th Annual JPMorgan Healthcare Conference Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference Cogentus Pharmaceuticals Completes $62.5 Million Private Financing Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario Low-income countries now have free, one-click access to Cochrane Library Parents' Smoking Boosts Child's Allergy Risk

Endoscope

Neuroview 1.2 mm Neuroendoscopes

...atch is a synthetic absorbable implant for the bri...s. Ethisorb Dura Patch is pliable, regardless of b...e, care must be taken, while implanting, to ensure...de is oriented towards the cortex or the spinal co...

IDS-300 Electrosurgical Generator

Medicine Products:

Endoscope Neuroview 1.2 mm Neuroendoscopes Ethisorb Dura Patch IDS-300 Electrosurgical Generator

Ikaria(R) Named Private Company of the Year by New Jersey Technolo...(ent of hepatorenal syndrome Type 1. Ikar...),Health